Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Definium Therapeutics (DFTX)

📈 Analyst William Blair reiterated a Buy rating on Biogen (BIIB) with shares closing at $192.59.

📊 Biogen currently holds a Moderate Buy consensus with an average price target of $217.26, implying 14.5% upside.

💼 TipRanks analyst Myles Minter has a track record of a 38.2% average return and 62.4% success rate in Healthcare.

📉 Definium Therapeutics (DFTX) shares closed last Friday at $22.19 ahead of analyst commentary.

🤝 JonesTrading's Justin Walsh reiterated a Buy rating on Definium with a price target set at $61.00.

🌟 Analyst Justin Walsh is rated as a 5-star performer by TipRanks with a 20.8% average return.

📈 Definium Therapeutics carries a Strong Buy consensus with an average price target of $40.00, representing 75% upside.

💡 Biogen recently received FDA extension approvals for its lecanemab-irmb submission (sBLA).

🔄 Market activity includes Eisai and Biogen announcing FDA review extensions alongside other sector updates.

📊 Biogen's stock has seen multiple upgrades including a move from Hold to Buy by Freedom Broker.

📈 Truist Financial recently raised Biogen's price target from $189 to $190.

💰 Citi analysts increased Biogen's price target from $190 to $200 in the same period.

⚠️ The article notes that it contains syndicated press releases and third-party materials not reviewed by The Globe and Mail.

Bullish Signals
  • William Blair analyst Myles Minter has reiterated a Buy rating on Biogen (BIIB), with a price target consensus of $217.26 representing a 14.5% upside from current levels.
  • TipRanks upgraded Biogen to a Buy rating on April 29 with a price target of $202.00, reinforcing positive analyst sentiment.
  • Definium Therapeutics (DFTX) has achieved a Strong Buy consensus with an average price target of $40.00, indicating a significant 75.0% upside potential from the last Friday's close at $22.19.
  • JonesTrading analyst Justin Walsh has maintained a Buy rating on Definium Therapeutics, citing its strong growth potential in the healthcare sector.
  • Biogen recently received an FDA extension of review period for lecanemab-irmb sBLA, providing a positive regulatory catalyst.
Risk Factors
  • Despite a Moderate Buy consensus, the price target consensus of $217.26 represents only a 14.5% upside from current levels, suggesting limited analyst growth expectations.
  • Recent upgrades from other firms, such as OpenAI upgrading Biogen to a Buy with a $202.00 price target on April 29, are significantly lower than the prevailing market consensus target of $217.26.
  • While several firms raised their price targets for Biogen (e.g., Truist and Citi), these increases were marginal, rising only $1 to $10 at a time, indicating cautious sentiment rather than strong bullish conviction.
  • The news feed indicates shifting sector dynamics with Eisai and Definium Therapeutics receiving attention alongside Biogen, potentially introducing competitive pressure or distraction for the company.
Full Analysis
William Blair analyst Myles Minter has reiterated a Buy rating for Biogen (BIIB), with the stock closing at $192.59 last Friday. Minter is identified as a top 100 analyst on TipRanks, boasting an average return of 38.2% and a success rate of 62.4%, while covering the Healthcare sector alongside other biotech firms like Contineum Therapeutics and CAMP4 Therapeutics. Biogen currently holds an analyst consensus of Moderate Buy with a price target of $217.26, indicating 14.5% upside potential from current levels; this follows an upgrade to Buy in late April with a $202 target. Separately, JonesTrading analyst Justin Walsh reiterated a Buy rating for Definium Therapeutics (DFTX) with a price target of $61.00 after the shares closed at $22.19 last Friday. Walsh is rated as a 5-star analyst on TipRanks with a 20.8% average return and covers various healthcare entities including NeuroOne Medical Technologies. Definium carries a Strong Buy consensus with an average price target of $40.00, representing a significant 75% upside from its current price level. Additional analyst activity highlighted includes Freedom Broker upgrading Biogen to Buy from Hold, Truist raising its price target for Biogen to $190, and Citi increasing its target to $200. Beyond the specific company reports, the syndicated content section lists other unrelated market updates, including an FDA extension for Biogen's lecanemab-irmb drug application, Remitly Global replacing Apellis in the S&P 600 index, and broader commentary on bank stocks and mining investments by other financial institutions.